CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in panel discussion and host one-on-one investor meetings at the 4th Annual Roth Healthc ...

CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present and host one-on-one investor meetings at the Lytham Partners Fall 2025 Investor Conference, ...

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 27 million shares of common stock and associated warrants, aiming to raise approximately $9 million to fund research and development and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 27,000,000 shares of common stock and Series E and Series F warrants, priced at $0.335 per share, with total gross proceeds expected to be around $9 million before expenses [1][3]. - The Series E Warrants and Series F Warrants will have an exercise price of $0.335 per share, with Series E Warrants expiring in five years and Series F Warrants expiring in 12 months [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a pipeline that includes two drug candidates, brilaroxazine (RP5063) and RP1208 [6].

Industry Overview - Biotech and healthcare stocks are responding positively to clinical trial progress, regulatory developments, and economic indicators, particularly with the Federal Reserve's first rate cut of 2025, which is expected to improve funding conditions for capital-intensive sectors like biotechnology [1] Company Highlights - **Sonnet BioTherapeutics Holdings Inc. (SONN)**: Shares increased by 11.19% in after-hours trading, reaching $7.85 after a regular session close of $7.06. The stock has a 52-week range of $1.08 - $19.30. The company expanded clinical evaluation of its lead candidate, SON-1010, for ovarian cancer, reporting a strong safety profile and a partial response at the highest dose level [2][3] - **Akari Therapeutics Plc (AKTX)**: Shares surged 11.58% in after-hours trading to $0.8855 after closing at $0.7936. The stock has a 52-week range of $0.5710 - $3.8500. The increase follows a provisional patent filing for its antibody-drug conjugate platform aimed at cancer treatment, which is expected to enhance its intellectual property and support the development of first-in-class ADCs [4][5] - **Safety Shot Inc. (SHOT)**: Shares rose 9.75% in after-hours trading to $0.3333 after closing at $0.3037. The company announced a strategic refresh of its Board of Directors with three new members to strengthen its capabilities in digital assets and operations [6][7] - **Reviva Pharmaceuticals Holdings Inc. (RVPH)**: Shares climbed 10.09% in after-hours trading to $0.4451 after closing at $0.4043. The stock has a 52-week range of $0.3000 - $4.2800. The price movement follows a revised analyst rating maintaining a "Speculative Buy" while lowering the price target from $14.00 to $7.00. Reviva's lead candidate, brilaroxazine, is being developed for multiple neuropsychiatric and respiratory indications [8][9][10] - **Cognition Therapeutics Inc. (CGTX)**: Shares rose 7.48% in after-hours trading to $1.58 after closing down at $1.47. The company is focused on its lead candidate, Zervimesine, for Alzheimer's disease, and recently closed a $30 million offering to support its Phase 3 development [12][13]

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 20 million shares of common stock and associated warrants, aiming to raise approximately $10 million to fund research and development activities and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 20,000,000 shares of common stock and Series C and D warrants, priced at $0.50 per share, with total gross proceeds expected to be around $10 million before expenses [1]. - Series C Warrants and Series D Warrants will have an exercise price of $0.50 per share, with Series C Warrants expiring in five years and Series D Warrants expiring in 12 months [2]. - The closing of the offering is anticipated on or about June 27, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [6]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house and protected by composition of matter patents in multiple regions [6].

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. plans to offer shares of its common stock and warrants in a public offering to fund research and development activities and for general corporate purposes [1][2]. Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [5]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house and have been granted composition of matter patents in multiple regions [5]. Offering Details - The offering will be conducted under an effective shelf registration statement on Form S-3, filed with the U.S. Securities and Exchange Commission (SEC) [3]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [2].

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a presentation scheduled at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference [1][2]. Company Overview - Reviva is engaged in discovering, developing, and commercializing next-generation therapeutics targeting diseases that pose significant burdens to society and patients [2]. - The company's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [2]. - Reviva has secured composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [2]. Conference Details - The H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference will feature a pre-recorded presentation by Reviva's CEO, Laxminarayan Bhat, available on-demand starting June 16, 2025 [2]. - The conference is virtual and registration is required for access [2].

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][2]. Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [2]. - The company has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [2]. Upcoming Events - Reviva's CEO, Laxminarayan Bhat, will participate in the Benchmark Healthcare House Call Virtual Investor Conference on May 29, 2025, at 11:15 a.m. ET [2]. - The company will also present at the Lytham Partners Spring 2025 Investor Conference on the same day at 2:00 p.m. ET [2].

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][2] - The company will participate in a fireside chat at the A.G.P. Healthcare Company Showcase on May 21, 2025, at 2:00 p.m. EST [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [2] - The company has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [2]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][2]. Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [2]. - The company has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [2]. Upcoming Events - Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present at the Citizens Life Sciences Conference on May 8, 2025, at 10:30 a.m. ET in New York, NY [1][2].